Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase

Introduction: Childhood chronic myeloid leukemia (CML) accounts for less than 3% of all childhood leukemias, hence, data on imatinib (IM) in adult CML patients has been largely extrapolated to children. We have analyzed our data to add to the existing literature. Aims: Primary objective is to assess...

Full description

Bibliographic Details
Main Authors: Vijay Gandhi Linga, Ranga Raman Ganta, Krishnamani Iyer Kalpathi, Sadashivudu Gundeti, Senthil J Rajappa, Raghunadharao Digumarti, Tara Roshni Paul, Ashwani Tandon
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2014-01-01
Series:South Asian Journal of Cancer
Subjects:
Childhood chronic myeloid leukemia
cytogenetic responses
imatinib mesylate
survival
Online Access:http://journal.sajc.org/article.asp?issn=2278-330X;year=2014;volume=3;issue=4;spage=203;epage=205;aulast=Linga

Internet

http://journal.sajc.org/article.asp?issn=2278-330X;year=2014;volume=3;issue=4;spage=203;epage=205;aulast=Linga

Similar Items